Machine learning-driven evaluation of protein kinase D3 as a co-diagnostic biomarker in hepatocellular carcinoma.

Subsequently, we collected a total of 392 clinical plasma samples from healthy individuals, patients with cirrhosis or decompensated cirrhosis, and patients with hepatocellular carcinoma.

Plasma PRKD3 levels were then determined across hepatocellular carcinoma patients and individuals at high risk of developing the disease.

The results revealed significantly elevated PRKD3 concentrations in patients with cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma compared to healthy controls ( P <0.01).

The areas under the receiver operating characteristic (ROC) curve for these three groups were 0.8107, 0.7899, and 0.7177, respectively.